Perspective Therapeutics Reports Q2 Loss

Perspective Therapeutics (NYSEMKT:CATX), a clinical-stage company focused on targeted radiopharmaceutical cancer therapies, reported results for Q2 2025 on August 13, 2025. The company posted GAAP revenue above analyst forecasts, while expenses rose sharply, reflecting expanded research and clinical activities. Revenue (GAAP) reached $0.3 million, beating the $0.2 million analyst estimate. EPS (GAAP) was -$0.29 per share, exceeding the analyst estimate of -$0.29. Net loss (GAAP) expanded compared to Q2 2024, driven by higher investment in trials and related administrative costs. Overall, the quarter underscored advancement in clinical trials, but highlighted ongoing expenditures outpacing revenue as the company moves through early-stage development. Source: Analyst estimates for the quarter provided by FactSet. Perspective Therapeutics develops targeted radiopharmaceutical therapies for cancer using a proprietary platform built around the alpha-emitting isotope lead-212 (212Pb). This approach uses radioactive particles to both diagnose and destroy cancer cells, referred to as "theranostics," aiming for precise tumor targeting with reduced toxicity.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool